Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10040654 | 0.89 | FAAH (0.41) | TP53MAPTLMNAFAAHCYP2C9 | |
| SCHEMBL10040569 | 0.86 | FAAH (0.46) | GPR119TP53MAPTLMNATDP1 | |
| SCHEMBL10040552 | 0.86 | MAPT (0.53) | GPR119TP53MAPTFAAHCYP2C9 | |
| SCHEMBL10040653 | 0.85 | MAPT (0.40) | MAPTLMNAFAAHCYP2C9HDAC4 | |
| SCHEMBL1653357 | 0.84 | TP53 (0.46) | GPR119TP53MAPTLMNATDP1 | |
| SCHEMBL10040555 | 0.83 | LMNA (0.55) | MAPTLMNAPOLBKMT2A | |
| SCHEMBL1653017 | 0.83 | GPR119 (0.42) | GPR119TP53MAPTLMNAFAAH | |
| SCHEMBL17151678 | 0.81 | GPR119 (0.55) | GPR119TP53MAPTLMNAFAAH | |
| SCHEMBL10040562 | 0.79 | SMN1; SMN2 (0.46) | GPR119LMNAFAAHKMT2A | |
| SCHEMBL12231313 | 0.79 | TP53 (0.54) | TP53MAPTLMNATDP1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2564849-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH PAINS IN URINARY ORGANS | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | claimed |
| US-20130030006-A1 | AGENT FOR PREVENTING OR TREATING DISEASES ACCOMPANIED BY URINARY PAIN | ASTELLAS PHARMA INC. (JP) | 2013-01-31 | — | — | US | claimed |
| EP-2308869-B1 | AZOLE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-19 | — | — | EP | claimed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | claimed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | claimed |
| EP-2564849-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH PAINS IN URINARY ORGANS | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130030006-A1 | AGENT FOR PREVENTING OR TREATING DISEASES ACCOMPANIED BY URINARY PAIN | ASTELLAS PHARMA INC. (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2308869-B1 | AZOLE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2308869-A1 | AZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | GPR119 159/4885TP53 4817/4885MAPT 2507/4885 |
| US-20130030006-A1 | AGENT FOR PREVENTING OR TREATING DISEASES ACCOMPANIED BY URINARY PAIN | FAAH, FAAH2, PTGS1 | GPR119 1734/4885TP53 3845/4885MAPT 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.